Results 11 to 20 of about 2,075,366 (204)

Suspecting and diagnosing transthyretin amyloid cardiomyopathy (ATTR-CM) in India: An Indian expert consensus. [PDF]

Indian Heart J, 2022
Transthyretin cardiac amyloidosis (ATTR-CM) is a rare and under-recognized disorder characterized by the aggregation of transthyretin-derived insoluble amyloid fibrils in the myocardium. Heterogeneity of symptoms at presentation, makes its diagnosis often delayed.
Chander Mohan J, Dalal J, Chopra VK, Narasimhan C, Kerkar P, Oomman A, Ray Fcsi S, Sharma AR, Dougall P, Simon S, Verma Drm A, Radhakrishnan V.   +11 more
europepmc   +3 more sources

Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial. [PDF]

Circulation
BACKGROUND: In the phase 3 randomized controlled study ATTRibute-CM (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy), acoramidis, a transthyretin stabilizer, demonstrated significant efficacy on the primary end point ...
Judge DP, Gillmore JD, Alexander KM, Ambardekar AV, Cappelli F, Fontana M, García-Pavía P, Grodin JL, Grogan M, Hanna M, Masri A, Nativi-Nicolau J, Obici L, Hvitfeldt Poulsen S, Sarswat N, Shah K, Soman P, Lystig T, Cao X, Wang K, Pecoraro ML, Tamby JF, Katz L, Sinha U, Fox JC, Maurer MS.   +25 more
europepmc   +2 more sources

Functionally Limiting Symptoms and Inability to Independently Complete Daily Activities Increase the Burden Felt by Caregivers to Patients with ATTR-CM. [PDF]

Cardiol Ther
Introduction The Burden of Disease survey characterized the humanistic burden of transthyretin amyloid cardiomyopathy (ATTR-CM) in 208 international patients not receiving disease-modifying therapy and their primary caregivers.
Cappelli F, Ponti L, Smorti M, Hsu K, Damy T, Verheyen N, Wang R, Kumar N, Munteanu C, Burden of Disease Study Investigators.   +9 more
europepmc   +2 more sources

Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups [PDF]

Orphanet Journal of Rare Diseases, 2021
Background Transthyretin amyloidosis, or ATTR, is a progressive and debilitating rare proteopathy generally manifested as either transthyretin amyloid polyneuropathy (ATTR-PN) or transthyretin amyloid cardiomyopathy (ATTR-CM).
David Rintell, Dena Heath, Florencia Braga Mendendez, Elizabeth Cross, Theodore Cross, Vincent Knobel, Bruno Gagnon, Cameron Turtle, Alan Cohen, Edward Kalmykov, Jonathan Fox   +10 more
doaj   +2 more sources

A real-world study of tafamidis in people with transthyretin amyloid cardiomyopathy (ATTR-CM) with heart and nerve symptoms: a plain language summary. [PDF]

Future Cardiol
Plain Language Summary What is this summary about? This summary describes results from The Transthyretin Amyloidosis Outcomes Survey (THAOS for short).
Wixner J, Dispenzieri A, Amass L, Carlsson M, Riley S, Powers E, Kelly JW.   +6 more
europepmc   +2 more sources

Effect of Timely Availability of TTR-Stabilizing Therapy on Diagnosis, Therapy, and Clinical Outcomes in ATTR-CM. [PDF]

J Clin Med
Highlights  What is known? Tafamidis, a transthyretin stabilizer, reduces cardiovascular morbidity and mortality in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).  What is new?
Dobner S, Zarro S, Wieser F, Kassar M, Alaour B, Wiedemann S, Bakula A, Caobelli F, Stortecky S, Gräni C, Hunziker L, Bernhard B.   +11 more
europepmc   +2 more sources

Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review. [PDF]

Cardiol Ther, 2021
Introduction: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, fatal and under-recognized disease. This targeted literature review assessed the extent and consequences of diagnostic delay and misdiagnosis in ATTR-CM.
Rozenbaum MH, Large S, Bhambri R, Stewart M, Whelan J, van Doornewaard A, Dasgupta N, Masri A, Nativi-Nicolau J.   +8 more
europepmc   +3 more sources

Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis [PDF]

Orphanet Journal of Rare Diseases, 2022
Background Transthyretin cardiac amyloidosis, also known as transthyretin cardiomyopathy (ATTR-CM) is a poorly-recognized disease with delayed diagnosis and poor prognosis.
Suk-Chan Jang, Jin Hyun Nam, Seung-Ah Lee, Dasom An, Hye-Lin Kim, Sun-Hong Kwon, Eui-Kyung Lee   +6 more
doaj   +2 more sources

ATTR-CM, HFpEF, and Clinical Cardiology: It Is Not a Moment, It Is a Movement. [PDF]

JACC CardioOncol, 2021
Nayak GS.
europepmc   +4 more sources

Real‐world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study

ESC Heart Failure
Aims Data on the clinical profiles of patients with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) in the post‐approval era of tafamidis 61 mg are lacking.
Richard J. Nies, Svenja Ney, Ingrid Kindermann, Yvonne Bewarder, Angela Zimmer, Fabian Knebel, Katrin Hahn, Sebastian Spethmann, Peter Luedike, Lars Michel, Tienush Rassaf, Maria Papathanasiou, Stefan Störk, Vladimir Cejka, Amin Polzin, Fabian Voss, Malte Kelm, Bernhard Unsöld, Christine Meindl, Michael Paulus, Ali Yilmaz, Bishwas Chamling, Caroline Morbach, Roman Pfister   +23 more
doaj   +2 more sources